[1]Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,Botnar Research Centre,University of Oxford,Oxford OX1 2JD,United Kingdom;
[2]Department of Rheumatology,Hospital de Santa Maria,CHLN,Lisbon Academic Medical Centre,1649-035 Lisbon,Portugal;
[1]Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,Botnar Research Centre,University of Oxford,Oxford OX1 2JD,United Kingdom;
[3]Department of Internal Medicine,Hospital das Caldas da Rainha,Centro Hospitalar Oeste,2500-176 Caldas da Rainha,Portugal;
[1]Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,Botnar Research Centre,University of Oxford,Oxford OX1 2JD,United Kingdom;
[4]Department of Rheumatology,St Vincent’s University Hospital,Dublin,Ireland;
[1]Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences,Botnar Research Centre,University of Oxford,Oxford OX1 2JD,United Kingdom;
Giant cell arteritis; Therapy; Disease management; Glucocorticoids; Immunosuppressive agents;